kabutan

SUSMED,Inc.(4263) Summary

4263
TSE Growth
SUSMED,Inc.
913
JPY
-5
(-0.54%)
Dec 5, 12:45 pm JST
5.88
USD
Dec 4, 10:45 pm EST
Result
PTS
outside of trading hours
913
Dec 5, 11:14 am JST
Summary Chart Historical News Financial Result
PER
PBR
3.66
Yield
ー%
Margin Trading Ratio
4.38
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
915 JPY 5.89 USD
Previous Close Dec 4
918 JPY 5.90 USD
High Dec 5, 9:01 am
918 JPY 5.91 USD
Low Dec 5, 9:10 am
908 JPY 5.85 USD
Volume
17,000
Trading Value
0.02B JPY 0.10M USD
VWAP
911.84 JPY 5.88 USD
Minimum Trading Value
91,300 JPY 588 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
79
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
668
1-Year High Jul 29, 2025
12,387
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 155,400 1,151,800 7.41
Nov 21, 2025 149,700 1,163,400 7.77
Nov 14, 2025 161,800 1,145,100 7.08
Nov 7, 2025 157,700 1,179,000 7.48
Oct 31, 2025 167,500 1,151,400 6.87
Company Profile
SUSMED, Inc. develops therapeutic applications for patients and provides systems to streamline pharmaceutical development. The company collaborates with pharmaceutical firms.
Sector
Information & Communication
SUSMED, Inc. focuses on developing therapeutic applications and providing support systems for pharmaceutical development. Their insomnia treatment application has received medical device approval and is preparing for insurance coverage. The company is currently developing multiple therapeutic applications, including an exercise therapy app for breast cancer patients and an ACP provision app. SUSMED, Inc. has developed and offers a general-purpose clinical trial system to improve the efficiency of clinical trials, as well as an AI platform called "Awesome Intelligence" for medical data analysis. The company is also working on implementing a remote clinical trial system utilizing blockchain technology. Additionally, SUSMED, Inc. provides DTx development support services for pharmaceutical companies and research institutions.